Certainty index
Very low certainty — page 2
The Institute has very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate. In this series a very low rating most often reflects an absence of controlled human evidence rather than conflicting evidence.
Graded outcomes
53 documents · page 2 of 2
Table 1. Outcomes and syntheses graded at very low certainty, on this page.
| Document | Type | Effect or conclusion as recorded |
|---|---|---|
| NAD+ (nicotinamide adenine dinucleotide) in mitochondrial disease | Evidence extract | No assessable randomised evidence identified for administered NAD+ |
| Glutathione in immune modulation | Evidence extract | No assessable randomised evidence for immune outcomes |
| Glutathione in ageing | Evidence extract | No randomised evidence for any ageing endpoint |
| 5-amino-1MQ in obesity | Evidence extract | No human trial of any kind identified |
| 5-amino-1MQ in type 2 diabetes | Evidence extract | No human trial identified |
| 5-amino-1MQ in ageing | Evidence extract | No human trial identified |
| Melanotan-II in sexual dysfunction | Evidence extract | No adequately powered randomised trial identified for this compound |
| Melanotan-II in obesity | Evidence extract | No randomised trial identified |
| Human evidence for BPC-157 | Synthesis | The Institute conducted a systematic search for randomised controlled trials of BPC-157 in any human population and indication and identified no trial that met inclusion criteria for which a… |
| Clinical evidence for growth-hormone secretagogues supplied for research | Synthesis | The clinical development of every compound in this group was directed at diagnosis of growth-hormone deficiency, at a specific disease indication, or at nothing beyond phase 1. The Institute… |
| Nationally registered neuropeptides and the retrievability of their evidence base | Synthesis | For each compound in this group the Institute was able to establish that a national registration exists and was not able to retrieve a trial report containing a protocol, a randomisation procedure… |
| Semax in cognitive performance and neuroprotection: effect on the anchor outcome | Synthesis | Very low certainty evidence from 2 contributing trials bears on the effect of Semax on the anchor outcome for cognitive performance and neuroprotection. The estimate the Institute carries in the… |
| Semax in cognitive performance and neuroprotection: tolerability and discontinuation | Synthesis | Very low certainty evidence from 2 contributing trials bears on tolerability. Discontinuation for adverse events is reported in the summary-of-findings table alongside the efficacy outcomes rather… |
page 2 of 2